The Value of Compliance During Chronic Administration of Acetylsalicylic Acid In Patients With Acute Coronary Syndrome: Results of The Study "FORPOST"

Found low compliance of admission to long-term acetylsalicylic acid (ASA) in patients with acute coronary syndrome (ACS): 74.9% of patients reported that the suspended or completely stopped taking the drug, and only 16.2% were fully committed to the long-term therapy with ASA. Patients are significantly more likely to discontinue conventional and buffered forms of ASA compared with intestinal-soluble forms of the drug (odds ratio - OR=1.81, 95% confidence interval - CI: 1.20 to 2.72; p=0,0027). The most common causes of low noncompliance were to receive ASA or the development of fear of adverse drug reactions (ADRs) - 47.1%, and the forgetfulness of the patients taking the drug regularly (25.4%). When receiving enteric forms of ASA NLR developed significantly less than in the case of buffered (OR 0.49, 95% Cl, 0.35 to 0,69; p=0,00002) and "ordinary" (OR 0.21, 95 % Cl 0.13 to 0,33; p=0,00001) forms of ASA. Compliance of the highest among all the drugs ASA, according to estimates by using a 10-point visual analog scale, were observed in enteric-coated forms of ASA (average score of 8.3 +/- 1.4). Some of the lowest noncompliance were noted to receive the "regular" aspirin tablet (6.9 +/- 1.4 points).